What Is Oxonol? MGM-15, Mitragynine and the Brand Name

Oxonol is a commercial name used for products described as containing MGM-15. MGM-15 and mitragynine are distinct compounds. Check the formula and lab results instead of relying on the Oxonol brand name.

MGM-15

DEA identifies MGM-15 as dihydro-7-hydroxymitragynine, a synthetic derivative related to 7-OH. DEA temporarily placed MGM-15 in Schedule I effective August 26, 2026, together with MGPI and MGM-16.

Mitragynine

Mitragynine, often shortened to MIT, is a principal naturally occurring alkaloid in kratom leaf. MGM-15 is a different compound. Concentrated products should name the active compound, physical form, amount basis, and scope of the laboratory report.

7-OH

7-hydroxymitragynine is another opioid-active compound related to kratom chemistry. DEA's separate 2026 notice proposes thresholds for 7-OH in botanical and processed products, but that proposal had not become an effective temporary order as of September 19.

How to identify the active compound

• Check the active-compound name and whether the amount applies per piece, serving, or package.
• The laboratory report connects the finished item or source material to a lot or sample ID and supplies the date, units, and method limits.
• Current federal and state documents establish the compound's legal status.

MGM-15 entered federal Schedule I on August 26, 2026, making the earlier “legal 7-OH alternative” description outdated.

Sources and further reading

• temporary order
• threshold-comment extension
• 2025 study of commercial tablets sold as MGM products
• description of its own Oxonol formula